The PennZone

MIAMI - PennZone -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

On August 26^th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.

More on The PennZone

• Kyle Schwarber Surprises Local Fan After Heartbreaking Loss
• Custom Woodworker Launches Updated Website
• Boston Industrial Solutions' Natron® 717N Series UV LED Ink Receives CPSIA Certification
• purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
• Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village

This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.  Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.

NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.

In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.

NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting.  These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05).  Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.

HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.

More on The PennZone

• UK Financial Ltd Publishes Maya Preferred Public Proof Package and CoinMarketCap Supply Verification Evidence
• Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
• Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
• Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
• CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets

NRX-101 for Treatment of Chronic Pain:

In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain.  Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.

During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.

Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.

NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.

Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website